For example, researchers are studying the inflammatory benefits of obesity drugs for conditions such as a serious form of liver disease, cardiovascular outcomes and Alzheimer's, among others, Seigerman wrote
Neither compound has been evaluated or approved by the FDA for any use
Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, Renn T, ten Cate H, Spronk HM
Transitioning to Phase 3
Most patients find they diminish after the first month
Virta Health Announces First-of-its-Kind Peer-Reviewed Study Proving Its Approach Is an Effective Off-Ramp From GLP-1s for Sustained Weight Loss Company builds on nearly 10 years of GLP-1 experience, expanding its Sustainable Weight Loss solution to deliver medication-free and medication-assisted weight loss Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the companys approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1s), including Ozempic